Core Viewpoint - Shenyin Biological (688098.SH) experienced a significant intraday drop of 6.31% to 10.24 yuan due to a planned share reduction by a major shareholder, UBI, to meet funding needs for clinical trials and commercialization of innovative drugs, including an Alzheimer's peptide vaccine [1] Summary by Relevant Sections - **Shareholder Actions** - UBI, a shareholder holding more than 5% of the company, plans to reduce its holdings by up to 4.1064 million shares through centralized bidding and up to 8.2129 million shares through block trading, totaling a maximum reduction of 12.3193 million shares, which represents 3% of the company's total share capital [1] - **Purpose of Share Reduction** - The share reduction is aimed at funding the clinical trials and commercialization efforts for original innovative drugs, as well as accelerating the construction of manufacturing bases in collaboration with partners in China [1] - **Timeline for Share Reduction** - The reduction period is set from November 13, 2025, to February 12, 2026, with the shares being sourced from those acquired prior to the IPO [1]

Core Viewpoint - Multiple shareholders across various companies are planning to reduce their stakes, indicating potential shifts in investor confidence and market dynamics [1] Shareholder Reductions - Wan Ye Enterprise: Shareholder Sanlin Wan Ye plans to reduce a total of 5.2059 million shares [1] - Kesi Technology: Liang Hongjian intends to reduce 1% of the company's shares [1] - Jindan Technology: Guangzhou Chengxin plans to reduce no more than 2.3866 million shares [1] - Xuantai Pharmaceutical: Qihe Venture plans to reduce a total of 3.131 million shares [1] - Hangzhou Jiebai: Chairman and General Manager Bi Ling plans to reduce a total of no more than 375,000 shares [1] - Jialian Biological: Shareholder UBI plans to reduce no more than 3% of shares [1] - Puyuan Information: Liu Yadong and his concerted actions plan to reduce a total of 0.89% of shares [1] - Zhifan Technology: Director Huang Yong plans to reduce no more than 2.9 million shares [1] - Lanshi Heavy Industry: Shareholder Hualing Xianggang plans to reduce no more than 1% of shares [1] - Biyi Micro: Shareholder Fang Guang Erqi plans to reduce a total of 1.50% of shares [1] - Xinghuo Technology: Shareholder Tie Xiaorong plans to reduce a total of 37.2298 million shares [1] - Henglian Shares: Multiple shareholders plan to reduce their stakes [1] - Jucheng Shares: Wuhan Luojia plans to reduce a total of 4.1241 million shares [1] Financial Performance - Xuanji Information: Reported a net loss of 173 million yuan for the first three quarters [1] - Meilixin: Reported a net loss of 110 million yuan for the third quarter [1]

Group 1 - On October 22, no A-share listed companies disclosed any increase in shareholding [1] - A total of 10 A-share listed companies announced share reductions, including Tai Lingwei, Jindan Technology, Shenlian Biology, Qianyuan Pharmaceutical, Hengsheng Energy, Zhengfan Technology, Lanshi Heavy Industry, Haiguo Co., Ganfeng Lithium, and Hengsuo Co. [1] Group 2 - Tai Lingwei's second largest shareholder, the National Big Fund, plans to reduce its stake by no more than 2% [2] - Jindan Technology's shareholder, Guangzhou Chengxin, intends to reduce its stake by no more than 1.05% [2] - Shenlian Biology's shareholder, UB, plans to reduce its stake by no more than 3% [2] - Qianyuan Pharmaceutical's shareholder, Weng Zhangguo, intends to reduce its stake by no more than 3% [2] - Zhengfan Technology's directors and supervisors plan to collectively reduce their stake by no more than 1.88% [2] - Hengsheng Energy's actual controller has already reduced his stake by 501,600 shares [2] - Lanshi Heavy Industry's shareholder, Hualing Xianggang, plans to reduce its stake by no more than 1% [2] - Haiguo Co.'s shareholder, Yujian Chuangtou, intends to reduce its stake by no more than 0.9965% [2] - Ganfeng Lithium's vice president, Fu Lihua, plans to reduce his stake by no more than 40,000 shares [2] - Hengsuo Co.'s shareholders collectively plan to reduce their stake by no more than 3% [2]

Group 1: Market Developments - Shenzhen aims to exceed a total market capitalization of 20 trillion yuan for listed companies by the end of 2027, an increase of 5 trillion yuan from previous targets [1] - The city plans to complete over 200 merger and acquisition projects with a total transaction value exceeding 100 billion yuan by 2027 [1] Group 2: Industry Performance - Shanghai's manufacturing output in the three leading industries grew by 8.5% year-on-year, with artificial intelligence manufacturing increasing by 12.8% [2] - The overall industrial output value in Shanghai increased by 5.7% year-on-year, with strategic emerging industries growing by 7.3% [2] Group 3: Company Announcements - UBI, a major shareholder of Shenyang Biological, plans to reduce its stake by up to 3% due to funding needs for clinical trials and commercialization of new drugs [8] - Sanwang Communication intends to repurchase shares worth between 20 million and 40 million yuan to support employee stock ownership plans [9] - Zhongjuxin reported a net profit increase of 152.24% year-on-year for the third quarter, with total revenue of 314 million yuan [10] Group 4: Financing Activities - Leju Robotics completed a Pre-IPO round of financing amounting to 1.5 billion yuan, with plans for an IPO underway [14] - Xunyu Technology announced over 100 million yuan in Pre-A round financing led by Sequoia China and Hillhouse Capital [15] - Haibo Pharmaceutical completed over 200 million yuan in B round financing, focusing on small molecule targeted drug development [18]

Core Viewpoint - UBI, a major shareholder of Shenlian Bio, plans to reduce its stake in the company to fund clinical trials and commercialization of its Alzheimer's peptide vaccine and related manufacturing base in China [1] Shareholder Reduction Plan - UBI intends to reduce its holdings by selling 4,106,440 shares through centralized bidding on the Shanghai Stock Exchange, which represents up to 1.00% of the total shares [1] - Additionally, UBI plans to sell 8,212,880 shares via block trading, accounting for up to 2.00% of the total shares [1] - The share reduction will occur within three months after a 15 trading day period following the announcement and will be at market price, not lower than the initial public offering price [1]

智通财经APP讯，申联生物(688098.SH)发布公告，美国联合生物医药公司(UNITED BIOMEDICAL, INC. 简称"UBI")因推进其阿尔茨海默症合成肽疫苗等原研创新药的临床试验、商业化布局及与中国的 合作伙伴加速与合成肽有关的生产制造基地的建设等而需资金投入，拟自公告披露之日起15个交易日之 后的3个月内以通过上海证券交易所交易系统以集中竞价交易方式减持公司股份410.64万股，不超过公 司股份总数的1%;以大宗交易方式减持公司股份821.29万股，不超过公司股份总数的2%。 ...

Core Viewpoint - The company Shenyuan Biological (688098.SH) announced that its shareholder UBI plans to reduce its stake in the company to fund clinical trials and commercialization of its Alzheimer's peptide vaccine and to accelerate the construction of a manufacturing base in collaboration with Chinese partners [1] Group 1 - UBI intends to reduce its holdings by 4.1064 million shares through centralized bidding on the Shanghai Stock Exchange, which accounts for no more than 1.00% of the company's total shares [1] - Additionally, UBI plans to sell 8.2129 million shares through block trading, representing no more than 2.00% of the company's total shares [1] - The share reduction will be conducted at market prices, not lower than the company's initial public offering price [1]

Core Viewpoint - UBI, a shareholder holding 10.52% of Shenyuan Biological (688098), plans to reduce its stake due to funding needs for clinical trials and commercialization of its Alzheimer's peptide vaccine and related manufacturing base in China [1] Group 1: Shareholder Actions - UBI intends to reduce its holdings by up to 4.1064 million shares through centralized bidding, representing 1% of the total share capital [1] - Additionally, UBI plans to reduce its holdings by up to 8.2129 million shares through block trading, accounting for 2% of the total share capital [1]

证券代码：688098 证券简称：申联生物 公告编号：2025-037 申联生物医药(上海)股份有限公司 持股 5%以上股东减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 股东持股的基本情况 截至本公告披露日，美国联合生物医药公司（UNITED BIOMEDICAL, INC. 以下简称"UBI"）持有申联生物医药（上海）股份有限公司（以下简称"公司" 或"申联生物"）43,199,898 股股份，占公司总股本的 10.52%。上述股份来源为 公司首次公开发行股票并上市前取得，且已于 2020 年 10 月 28 日后上市流通。 减持计划的主要内容 股东 UBI 因推进其阿尔茨海默症合成肽疫苗等原研创新药的临床试验、商 业化布局及与中国的合作伙伴加速与合成肽有关的生产制造基地的建设等而需 资金投入，拟自本公告披露之日起 15 个交易日之后的 3 个月内以通过上海证券 交易所交易系统以集中竞价交易方式减持本公司股份 4,106,440 股，不超过本公 司股份总数的 1.00%；以大 ...

Core Points - The core point of the announcement is that United BioPharma, a US-based company, holds 43.1999 million shares of Shenlian Bio, accounting for 10.52% of the total shares [1] Summary by Category Shareholding and Reduction Plan - United BioPharma plans to reduce its holdings due to funding needs, with a proposed reduction period from November 13, 2025, to February 12, 2026 [1] - The company intends to sell up to 4.1064 million shares through centralized bidding, representing 1.00% of the total shares [1] - Additionally, it plans to reduce up to 8.2129 million shares through block trading, which accounts for 2.00% of the total shares [1] - The total reduction will not exceed 12.3193 million shares, which is a maximum of 3% of the total shares, all of which were acquired before the IPO [1]